ALSO NOTED: GW Pharma to get Sativex review; BMS wins priority review;and much more...

> The UK's GW Pharmaceuticals says that Canadian regulators will consider approving its cannabis-based Sativex as a therapy for cancer pain. Report

> The FDA has given priority review status to Bristol-Myers Squibb's breast cancer drug ixabepilone. Report

> Roche and Chugai plan basic new research of Tamiflu in the wake of reports in Japan that the drug has been linked to abnormal behavior. Report

> Javelin Pharmaceuticals says that a late-stage study of its pain drug Rylomine demonstrated a reduction in postsurgical orthopedic pain. Report

And Finally… Richard Friedman, M.D., discusses how genetic testing may soon take much of the guesswork out of prescribing antidepressants. Article

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.